Rhode Island Chronicle

Prostate Cancer Market to Advance at Moderate CAGR During the Forecast Period (2022-2032) – Estimates DelveInsight | Novartis, ESSA Pharma, Roche, Merck, AstraZeneca, Orion, Advantagene, Astellas

 Breaking News
  • No posts were found

Prostate Cancer Market to Advance at Moderate CAGR During the Forecast Period (2022-2032) – Estimates DelveInsight | Novartis, ESSA Pharma, Roche, Merck, AstraZeneca, Orion, Advantagene, Astellas

June 01
08:40 2023
Prostate Cancer Market to Advance at Moderate CAGR During the Forecast Period (2022-2032) - Estimates DelveInsight | Novartis, ESSA Pharma, Roche, Merck, AstraZeneca, Orion, Advantagene, Astellas
Delveinsight Business Research LLP
As per DelveInsight, the Prostate Cancer Market is anticipated to evolve immensely in the coming years owing to the increasing number of cases of prostate cancer, the rising number of risk factors associated with prostate cancer, growing awareness regarding prostate cancer among men, and the launch of new therapies in the market.

Moreover, the increasing research and development activities, increasing technological advancements such as the incorporation of artificial intelligence (AI) in prostate cancer diagnosis, and government and non-government initiatives for prostate cancer among others are also anticipated to contribute immensely to the Prostate Cancer Market growth.

Some of the major pharma and biotech companies in the Prostate Cancer Market include Proteomedix, A3P Biomedical, GE HealthCare, Soteria Medical BV, Bio-Techne, F. Hoffmann-La Roche Ltd., Indica Labs Inc., OPKO HEALTH, INC., miR Scientific, LLC, MINOMIC®, Novartis AG, Johnson and Johnson Services, Inc., Astellas Pharma Inc., Cipla, AstraZeneca, Bayer AG, Zydus Cadila, Pfizer Inc., Avenda Health, The Sanpower Group, and others.

DelveInsight’s “Prostate Cancer Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Prostate Cancer market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers the emerging Prostate Cancer drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Prostate Cancer treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Prostate Cancer: An Overview

Prostate cancer begins when cells in the prostate gland—only found in males—start to grow uncontrollably. Almost all prostate cancers are adenocarcinoma. These cancers develop from the gland cells.

Some prostate cancers can grow and spread quickly, but most grow gradually. There are usually no symptoms during the early stages of cancer. However, if symptoms do appear, they usually involve one or more of the following: frequent urges to urinate, including at night, difficulty commencing and maintaining urination, blood in the urine, and painful urination, among several others symptoms.

Prostate Cancer Market Key Facts

  • Prostate Cancer is the most common type of cancer found in American men after skin cancer. The American Cancer Society estimates that roughly 191,930 new cases of prostate cancer diagnosed in the United States.

  • Nearly one in nine men will develop prostate cancer in their lifetime, though it is usually diagnosed after age 40. About 6 out of 10 cases are diagnosed in men aged 65 years or older; it is rare before age 40. The average age at the time of diagnosis is about 66 years.

  • According to the National Cancer Institute, approximately 10–20% of prostate cancer cases are castration-resistant, and up to 16% of these patients show no evidence that cancer has spread at the time of the castration-resistant diagnosis.

  • According to Prostate Cancer UK, over 47,500 men are diagnosed with prostate cancer every year—i.e. 129 men every day. One in eight men will be diagnosed with prostate cancer in their lifetime.

Prostate Cancer Market

Prostate Cancer Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Prostate Cancer market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Prostate Cancer market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Prostate Cancer Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Prostate Cancer epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Prostate Cancer Epidemiology, Segmented as –

  • Total Incident Cases of Prostate Cancer in the 7MM (2019–2032)

  • Stage-specific Incident Cases of Prostate Cancer in the 7MM (2019–2032) (E.g. Localized, Regional, Distant)

  • Grade-specific Incident Cases of Prostate Cancer in the 7MM (2019–2032) (E.g. Well differentiated, poor/undifferentiated, others)

  • Age-specific Incident Cases of Prostate Cancer in the 7MM (2019–2032)

  • Treatable cases of Prostate Cancer in the 7MM (2019–2032)

Prostate Cancer Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Prostate Cancer market or expected to be launched during the study period. The analysis covers the Prostate Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the Prostate Cancer market with the most rapid drug uptake and the reasons behind the maximal use of the drugs. Additionally, it compares Prostate Cancer drugs based on their sale and market share.

The report also covers the Prostate Cancer pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Prostate Cancer Market Will Evolve and Grow by 2032 @ 


Prostate Cancer Therapeutics Analysis

The goals of pharmacotherapy for prostate cancer are to induce remission, reduce morbidity, and prevent complications. Agents used for the treatment of prostate cancer include the following: Androgen antagonists, Gonadotropin-releasing hormone (GnRH) agonists, Bisphosphonates, Antifungal agents, Chemo-therapeutic agents, Corticosteroids, and Immunologic agents.

To further improve the treatment scenario, several major pharma and biotech companies are developing therapies for Prostate Cancer. Currently, Merck is leading the therapeutics market with its Prostate Cancer drug candidates in the most advanced stage of clinical development.

Prostate Cancer Companies Actively Working in the Therapeutics Market Include

Advantagene, Advaxis, Inc., Allife Medical Science and Technology, Amgen, Arvinas Inc, Astellas Pharma, AstraZeneca, Bavarian Nordic, Bayer, Bayer Health Care, BeiGene, Blue Earth Diagnostics, Bracco Diagnostics, Inc, Bristol-Myers Squibb, Cancer Targeted Technology, Cardiff Oncology, Clarity Pharmaceuticals, Clovis Oncology, eFFECTOR Therapeutics, Eli Lilly and Company, Emtora Biosciences, Epizyme, ESSA Pharma, Exelixis, Fortis Therapeutics, Inc., Genmab, Genovax, Harpoon Therapeutics, Hinova pharmaceuticals, Hoffmann-La Roche, Immunomedics, Innocrin Pharmaceutical, Janssen Research & Development, LLC, Jiangsu Hengrui Medicine Co., Laekna Limited, Leap Therapeutics, Luye Pharma Group, MacroGenics, Matrix Biomed, Merck & Co, Myovant Sciences/Takeda, Novartis, Nymox Pharmaceutical, Orion Pharma, Pfizer, Plexxikon, Regeneron Pharmaceuticals, RhoVac, Sanofi, Sophiris Bio, Suzhou Kintor Pharmaceuticals, Tavanta Therapeutics, Teneobio, Inc., Tracon Pharmaceuticals Inc., Trovagene, Vaccitech, Veru Inc., Zenith Epigenetics, and many others.

Emerging and Marketed Prostate Cancer Therapies Covered in the Report Include:

  • 177Lu-PSMA-617: Novartis

  • EPI-7386: ESSA Pharma

  • Ipatasertib (RG7440): Hoffmann-La Roche

  • Keytruda: Merck Sharp & Dohme

  • Lynparza (olaparib): AstraZeneca/Merck Sharp & Dohme

  • ODM-208: Orion

  • Pembrolizumab: Merck & Co

  • ProstAtak: Advantagene

  • Rubraca (Rucaparib): Clovis Oncology

  • Talzoparib: Pfizer/Astellas Pharma

  • ZEN 3694: Zenith Epigenetics

And Many Others

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

Prostate Cancer Therapeutics Landscape



Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Prostate Cancer Competitive Intelligence Analysis

4. Prostate Cancer Market Overview at a Glance

5. Prostate Cancer Disease Background and Overview

6. Prostate Cancer Patient Journey

7. Prostate Cancer Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Prostate Cancer Treatment Algorithm, Current Treatment, and Medical Practices

9. Prostate Cancer Unmet Needs

10. Key Endpoints of Prostate Cancer Treatment

11. Prostate Cancer Marketed Therapies

12. Prostate Cancer Emerging Drugs and Latest Therapeutic Advances

13. Prostate Cancer Seven Major Market Analysis

14. Attribute Analysis

15. Prostate Cancer Market Outlook (In US, EU5, and Japan)

16. Prostate Cancer Access and Reimbursement Overview

17. KOL Views on the Prostate Cancer Market

18. Prostate Cancer Market Drivers

19. Prostate Cancer Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. 


Other Trending Healthcare Reports by DelveInsight

Candidemia Market

“Candidemia Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Candidemia market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Candidemia market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/